Quantification of chorea in Huntington's disease by power spectral analysis.
A spectral analysis technique for quantifying dyskinesia in patients with diagnosis of Hungtington's Disease (chorea) (H.D.) is described. Spectral analysis involves computation of the magnitude of abnormal involuntary movements (AIMS) and of their distribution in frequency. It has the advantage of providing an objective measure of such movements. Three H.D. patients under different drug regimens and three age-matched controls have been evaluated and representative time records and power spectra are presented. Analysis established marked differences in the amplitude and shape of the normal and patient spectra. In addition, spectral analysis proved sensitive to differences in drug treatments among patients suggesting its additional use in evaluating the efficacy of therapeutic agents in the treatment of movement disorders.
D000328:Adult; D000368:Aged; D003975:Diazepam / Q000627:therapeutic use; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D006816:Huntington Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D008653:Mesoridazine / Q000627:therapeutic use; D008722:Methods; D008875:Middle Aged; D009069:Movement Disorders / Q000175:diagnosis; D011346:Prochlorperazine / Q000627:therapeutic use; D013997:Time Factors; D014282:Trihexyphenidyl / Q000627:therapeutic use
D008653:Mesoridazine; D014282:Trihexyphenidyl; D006220:Haloperidol; D003975:Diazepam; D011346:Prochlorperazine